A sense of déjà vu: the debate surrounding state biosimilar substitution laws

A sense of déjà vu: the debate surrounding state biosimilar substitution laws

Collection:
Health Policy and Services Research
Series Title(s):
Insight on the issues (AARP Public Policy Institute)
Author(s):
Purvis, Leigh, author
Contributor(s):
AARP (Organization)
Public Policy Institute (AARP (Organization))
Publication:
Washington, D.C. : AARP Public Policy Institute, September 2014
Language(s):
English
Format:
Text
Subject(s):
Biological Products -- economics
Biological Products -- therapeutic use
Biosimilar Pharmaceuticals -- economics
Biosimilar Pharmaceuticals -- therapeutic use
Drug Costs
Drug Substitution
Legislation, Drug
United States
United States. Food and Drug Administration
United States.
Genre(s):
Technical Report
Abstract:
The Affordable Care Act created an approval pathway for less expensive generic versions of biologic drugs, known as biosimilars, or follow-on biologics. However, new state legislation that could greatly limit the savings from biosimilars has ignited a debate similar to the one that followed the passage of federal legislation that encouraged the development of traditional generic drugs.
Copyright:
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY-NC-ND license. (More information)
Extent:
1 online resource (1 PDF file (5 pages)).
NLM Unique ID:
101656652 (See catalog record)
Permanent Link:
http://resource.nlm.nih.gov/101656652